eXoZymes (NASDAQ:EXOZ) versus Molecular Partners (NASDAQ:MOLN) Head to Head Contrast

Molecular Partners (NASDAQ:MOLN) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Molecular Partners and eXoZymes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-51.40%	-45.21%
eXoZymes	N/A	-104.58%	-79.55%

Valuation and Earnings

This table compares Molecular Partners and eXoZymes”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65 million	35.23	-$61.39 million	($1.92)	-2.57
eXoZymes	$70,000.00	850.80	-$5.86 million	($0.77)	-9.21

eXoZymes has lower revenue, but higher earnings than Molecular Partners. eXoZymes is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Molecular Partners has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, eXoZymes has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Molecular Partners and eXoZymes, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1	1	2	0	2.25
eXoZymes	1	0	0	0	1.00

Molecular Partners currently has a consensus target price of $9.58, suggesting a potential upside of 94.39%. Given Molecular Partners’ stronger consensus rating and higher probable upside, research analysts clearly believe Molecular Partners is more favorable than eXoZymes.

Insider & Institutional Ownership

26.6% of Molecular Partners shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Molecular Partners beats eXoZymes on 8 of the 13 factors compared between the two stocks.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.